Montani David, Souza Rogerio, Binkert Christoph, Fischli Walter, Simonneau Gerald, Clozel Martine, Humbert Marc
Centre des Maladies Vasculaires Pulmonaires, UPRES EA 2705, Service de Pneumologie et Réanimation Respiratoire, Hôpital Antoine Béclère, Assistance Publique-Hôpitaux de Paris, Université Paris-Sud. 157 rue de la Porte de Trivaux, 92140 Clamart, France.
Chest. 2007 Jan;131(1):101-8. doi: 10.1378/chest.06-0682.
Pulmonary arterial hypertension (PAH) is a rare condition characterized by elevated pulmonary artery pressure leading to right-heart failure and death. Endothelin (ET)-1 has been shown to play a significant pathogenic role in PAH. ET-3 has not yet been investigated in PAH.
ET-1 and ET-3 plasma concentrations were measured in 33 PAH patients prior to any specific PAH therapy and in 9 control subjects. In PAH patients, hemodynamic parameters measured by right-heart catheterization, 6-min walk distance (6MWD), New York Heart Association (NYHA) functional class, and time until lung transplantation or death were recorded.
In patients with PAH, levels of ET-1 were increased while those of ET-3 were decreased, as compared to control subjects (p < 0.005 for both comparisons). ET-1/ET-3 ratio varied little in control subjects, while it increased threefold in PAH patients (p < 0.0001). ET-1 correlated positively with right atrial pressure (RAP), indexed total pulmonary resistance, and negatively with cardiac index and venous saturation of oxygen (Svo(2)). ET-3 correlated positively with 6MWD. ET-1/ET-3 ratio correlated positively with RAP, negatively with Svo(2) and 6MWD, and was also associated with NYHA functional class. ET-1/ET-3 ratio was associated with prognosis in this sample of PAH patients treated with specific therapies.
PAH is characterized by elevated ET-1 and ET-1/ET-3 ratio and decreased ET-3 plasma concentrations. All of them correlate with hemodynamic and clinical markers of disease severity. ET-1/ET-3 ratio might be a novel prognostic factor in PAH. These preliminary data should be validated in a large prospective multicenter cohort of PAH patients.
肺动脉高压(PAH)是一种罕见疾病,其特征为肺动脉压力升高,最终导致右心衰竭和死亡。内皮素(ET)-1已被证明在PAH中起重要的致病作用。而ET-3在PAH中的作用尚未得到研究。
在33例未经任何特定PAH治疗的PAH患者和9名对照受试者中测量ET-1和ET-3的血浆浓度。记录PAH患者经右心导管测量的血流动力学参数、6分钟步行距离(6MWD)、纽约心脏协会(NYHA)功能分级以及直至肺移植或死亡的时间。
与对照受试者相比,PAH患者的ET-1水平升高,而ET-3水平降低(两项比较p均<0.005)。对照受试者的ET-1/ET-3比值变化不大,而PAH患者的该比值增加了两倍(p<0.0001)。ET-1与右心房压力(RAP)、总肺阻力指数呈正相关,与心脏指数和静脉血氧饱和度(Svo₂)呈负相关。ET-3与6MWD呈正相关。ET-1/ET-3比值与RAP呈正相关,与Svo₂和6MWD呈负相关,并且还与NYHA功能分级相关。在接受特定治疗的该组PAH患者中,ET-1/ET-3比值与预后相关。
PAH的特征是ET-1升高、ET-1/ET-3比值升高以及ET-3血浆浓度降低。所有这些都与疾病严重程度的血流动力学和临床指标相关。ET-1/ET-3比值可能是PAH的一个新的预后因素。这些初步数据应在一个大型前瞻性多中心PAH患者队列中进行验证。